Research To Practice | Oncology Videos

Featuring perspectives from Dr Floor J Backes, including the following topics: Available data with and clinical investigator perspectives on trastuzumab deruxtecan for the management of gynecologic cancers (0:00) Patient-specific factors guiding treatment selection and sequencing for ovarian cancer (OC) (6:05) Management of adverse events associated with PARP inhibitor maintenance therapy for OC; safety concerns in the later-line setting (15:00) Management approaches for ocular toxicity and other adverse events associated with mirvetuximab soravtansine (20:28) Current role of upifitamab rilsodotin in the management of OC and available data with tumor treating fields (24:38) Investigator perspectives on the current chemotherapy shortage; recently published Phase III data with chemoimmunotherapy for endometrial cancer (29:11) Tisotumab vedotin for cervical cancer (36:34) CME information and select publications

Inside the Issue: Optimizing the Management of Metastatic Urothelial Bladder Cancer | Faculty Presentation 1: Immunotherapy-Based Strategies for Metastatic Urothelial Bladder Cancer (mUBC) — Terence Friedlander, MD CME information and select publications

Inside the Issue: Optimizing the Management of Metastatic Urothelial Bladder Cancer | Faculty Presentation 2: Available Data with, Ongoing Investigation of and Role of Other Novel Strategies for mUBC — Petros Grivas, MD, PhD CME information and select publications

Featuring perspectives from Dr Terence Friedlander and Prof Petros Grivas, including the following topics: Introduction (00:00) First-line treatment of metastatic urothelial bladder cancer (22:39) Second-line therapy and beyond (41:34) CME information and select publications

Featuring perspectives from Dr Heather McArthur, including the following topics: Investigator perspectives on recently presented data from clinical trials for HER2-positive localized and metastatic breast cancer (mBC) (0:00) Racial and ethnic differences in 21-gene Recurrence Score® and survival among patients with ER-positive breast cancer (28:31) Emerging data with CDK4/6 inhibitors for ER-positive, HER2-negative breast cancer (38:22) Final overall survival analysis from the TROPiCS-02 study of sacituzumab govitecan for ER-positive, HER2-negative mBC; TROP2 mRNA expression and association with clinical outcomes (1:03:22) CME information and select publications

Inside the Issue: Novel Agents, Approaches and Strategies in the Management of Higher-Risk Myelodysplastic Syndromes — Faculty Presentation 2: Future directions in the management of higher-risk MDS — Dr David Sallman CME information and select publications

Inside the Issue: Novel Agents, Approaches and Strategies in the Management of Higher-Risk Myelodysplastic Syndromes — Faculty Presentation 1: Current management of higher-risk myelodysplastic syndromes (MDS) — Guillermo Garcia-Manero, MD CME information and select publications

Featuring perspectives from Dr Guillermo Garcia-Manero and Dr David Sallman, including the following topics: Introduction (00:00) Biology of Acute Myeloid Leukemia/Myelodysplastic Syndromes (3:14) Assessment of Risk Status (14:17) Oral Hypomethylating Agents (HMAs) (22:24) HMA/Venetoclax; Other Combinations (31:26) Magrolimab/TP53 (45:12) CME information and select publications

Featuring a slide presentation and related discussion from Dr Hanny Al-Samkari, including the following topics: Indications for initiation of treatment for patients with immune thrombocytopenia (ITP) and selection of first-line therapy (0:00) Treatment algorithm for ITP in the second line and beyond (7:47) Role of thrombopoietin receptor agonists and fostamatinib for second- and later-line treatment of ITP (14:21) Novel investigational approaches for the treatment of ITP — efgartigimod, rilzabrutinib and ianalumab (28:24) CME information and select publications

Featuring perspectives from Dr Hanny Al-Samkari, including the following topics: Case: A woman in her mid 60s with a past medical history of hypertension and Sjögren's syndrome presents to emergency with diffuse petechiae in her extremities and the taste of iron in her mouth (0:00) Case: A man in his early 30s with chronic immune thrombocytopenia (ITP) who has been off therapy for 18 months with no constitutional symptoms presents for his 3-month follow-up with platelet count decreased to 29 x 109/L (3:26) Case: A woman in her mid 60s with chronic ITP who has received multiple treatments over a decade and is resistant to splenectomy presents for follow-up with a platelet count of 11 x 109/L (5:58) Characterizing immune dysfunction in patients with ITP (7:45) Perspectives on the approach to initial therapy for ITP (12:23) Treatment approaches beyond first-line therapy (17:34) Addressing symptoms and concerns beyond the issue of bleeding for patients with ITP (22:19) Role of splenectomy in the treatment of ITP (27:08) CME information and select publications